Rapport Therapeutics (NASDAQ:RAPP) Shares Down 7.4% – Here’s What Happened

Rapport Therapeutics, Inc. (NASDAQ:RAPP) dropped 7.4% during mid-day trading on Wednesday. The stock traded as low as $27.82 and last traded at $27.2110. 121,229 shares changed hands during mid-day trading, a decline of 69% from the average daily volume of 391,842 shares. The stock had previously closed at $29.37.

Key Stories Impacting Rapport Therapeutics

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 met both Phase 2 endpoints in bipolar mania. The treatment produced statistically significant improvements in mania-severity measures, and Rapport plans to advance the program into Phase 3. The results could substantially expand RAP-219’s potential beyond its epilepsy program. Rapport Therapeutics Phase 2 results
• Positive Sentiment: Analysts became more optimistic following the data. JonesTrading raised its price target from $50 to $82 and assigned a Buy rating. BTIG increased its target to $89, while HC Wainwright reaffirmed its Buy rating. The analyst consensus target is approximately $68.36, implying substantial potential upside if clinical development progresses successfully. BTIG Research price target increase
• Positive Sentiment: Company insiders made significant open-market purchases. CFO Troy Ignelzi bought 5,500 shares for $143,550, while four directors purchased a combined 52,594 shares. The purchases, worth roughly $1.57 million in total, may signal management confidence after the clinical update. SEC insider filings
• Neutral Sentiment: RAP-219’s planned Phase 3 development is an important milestone, but the company remains a clinical-stage biotechnology firm exposed to trial, regulatory, funding, and commercialization risks.
• Negative Sentiment: The clinical results may have been less decisive than some investors hoped. Commentary suggested that parts of the data narrowly met expectations, potentially limiting the rally. Rapport also remains unprofitable; its latest quarterly loss of $1.19 per share was worse than the $1.12 consensus estimate, and analysts expect a full-year loss of about $4.09 per share. Rapport bipolar mania data analysis

Analyst Ratings Changes

RAPP has been the subject of a number of research analyst reports. Wolfe Research began coverage on shares of Rapport Therapeutics in a research report on Thursday, October 15th. They set an “outperform” rating and a $50.00 price objective for the company. Wells Fargo & Company decreased their target price on Rapport Therapeutics from $51.00 to $50.00 and set an “overweight” rating on the stock in a research report on Wednesday. HC Wainwright restated a “buy” rating and set a $66.00 price target on shares of Rapport Therapeutics in a research note on Tuesday. JonesTrading upped their price target on Rapport Therapeutics from $50.00 to $82.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $86.00 price objective on shares of Rapport Therapeutics in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Rapport Therapeutics has a consensus rating of “Buy” and an average price target of $68.36.

Rapport Therapeutics Stock Up 5.9%

The business’s 50 day moving average price is $39.44 and its 200-day moving average price is $39.02.

Rapport Therapeutics (NASDAQ:RAPP) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.19) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07). Sell-side analysts forecast that Rapport Therapeutics, Inc. will post -4.09 earnings per share for the current year.

Insider Activity

In related news, CFO Troy Ignelzi acquired 5,500 shares of the firm’s stock in a transaction on Wednesday, October 21st. The shares were bought at an average cost of $26.10 per share, with a total value of $143,550.00. Following the completion of the acquisition, the chief financial officer owned 15,500 shares of the company’s stock, valued at $404,550. This trade represents a 55.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director John Maraganore acquired 9,411 shares of the stock in a transaction dated Thursday, October 22nd. The stock was bought at an average price of $26.45 per share, for a total transaction of $248,920.95. Following the completion of the purchase, the director owned 9,411 shares in the company, valued at approximately $248,920.95. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have purchased 58,094 shares of company stock valued at $1,566,358 and have sold 97,976 shares valued at $4,420,349. 12.48% of the stock is currently owned by company insiders.

Institutional Trading of Rapport Therapeutics

Large investors have recently bought and sold shares of the stock. AlphaCentric Advisors LLC lifted its holdings in shares of Rapport Therapeutics by 6.8% during the first quarter. AlphaCentric Advisors LLC now owns 6,438 shares of the company’s stock valued at $201,000 after acquiring an additional 408 shares during the period. Sterling Capital Management LLC grew its holdings in shares of Rapport Therapeutics by 597.9% in the 3rd quarter. Sterling Capital Management LLC now owns 984 shares of the company’s stock worth $33,000 after purchasing an additional 843 shares during the last quarter. KBC Group NV bought a new stake in shares of Rapport Therapeutics in the 1st quarter worth about $30,000. State of Wyoming acquired a new stake in shares of Rapport Therapeutics during the 2nd quarter worth about $65,000. Finally, Swiss National Bank increased its position in shares of Rapport Therapeutics by 3.5% during the 1st quarter. Swiss National Bank now owns 56,500 shares of the company’s stock worth $1,768,000 after purchasing an additional 1,900 shares in the last quarter.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.